Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | jumonji domain containing protein | 0.0042 | 0.0019 | 0.0019 |
Mycobacterium tuberculosis | Probable thymidine phosphorylase DeoA (tdrpase) (pyrimidine phosphorylase) | 0.6366 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0053 | 0.0035 | 1 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0037 | 0.001 | 0.1976 |
Echinococcus multilocularis | lysine specific demethylase 5A | 0.0037 | 0.001 | 0.001 |
Onchocerca volvulus | Alhambra homolog | 0.003 | 0 | 0.5 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0037 | 0.001 | 0.1313 |
Mycobacterium leprae | Probable anthranilate phosphoribosyltransferase TrpD | 0.1797 | 0.2788 | 0.5 |
Brugia malayi | hypothetical protein | 0.0034 | 0.0006 | 0.0543 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0053 | 0.0035 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.0034 | 0.6709 |
Schistosoma mansoni | jumonji domain containing protein | 0.0079 | 0.0077 | 1 |
Brugia malayi | hypothetical protein | 0.0053 | 0.0035 | 0.3254 |
Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0099 | 0.0109 | 0.0109 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0053 | 0.0035 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0053 | 0.0035 | 0.5 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0063 | 0.0051 | 1 |
Brugia malayi | jmjC domain containing protein | 0.0037 | 0.001 | 0.0925 |
Giardia lamblia | PHD finger protein 15 | 0.003 | 0 | 0.5 |
Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0099 | 0.0109 | 0.0109 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0053 | 0.0035 | 1 |
Echinococcus granulosus | lysine specific demethylase 5A | 0.0037 | 0.001 | 0.001 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0053 | 0.0035 | 0.5 |
Brugia malayi | jmjC domain containing protein | 0.0099 | 0.0109 | 1 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0037 | 0.001 | 0.1313 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.0035 | 0.6952 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0053 | 0.0035 | 1 |
Echinococcus multilocularis | jumonji domain containing protein | 0.0042 | 0.0019 | 0.0019 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0053 | 0.0035 | 0.5 |
Echinococcus multilocularis | thymidine phosphorylase | 0.6366 | 1 | 1 |
Mycobacterium ulcerans | thymidine phosphorylase | 0.6366 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 3000 nM | Compound was tested for cytotoxicity against paclitaxel sensitive KB-3-1 cell line | ChEMBL. | 15261301 |
IC50 (functional) | > 3000 nM | Compound was tested for cytotoxicity against paclitaxel resistant KB-8-5 cell line expressing P-glycoprotein | ChEMBL. | 15261301 |
IC50 (functional) | > 3000 nM | Compound was tested for cytotoxicity against paclitaxel resistant KB-V1 cell line expressing P-glycoprotein | ChEMBL. | 15261301 |
IC50 (functional) | > 3000 nM | Compound was tested for cytotoxicity against paclitaxel sensitive KB-3-1 cell line | ChEMBL. | 15261301 |
IC50 (functional) | > 3000 nM | Compound was tested for cytotoxicity against paclitaxel resistant KB-8-5 cell line expressing P-glycoprotein | ChEMBL. | 15261301 |
IC50 (functional) | > 3000 nM | Compound was tested for cytotoxicity against paclitaxel resistant KB-V1 cell line expressing P-glycoprotein | ChEMBL. | 15261301 |
Inhibition (functional) | = 27 % | Compound was evaluated for the ability to inhibit cell-free tubulin polymerisation at 0.5 uM | ChEMBL. | 15261301 |
Inhibition (functional) | = 27 % | Compound was evaluated for the ability to inhibit cell-free tubulin polymerisation at 0.5 uM | ChEMBL. | 15261301 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 15261301 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.